Skip to main navigation Skip to search Skip to main content

Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial

  • COV-BARRIER Study Group

Research output: Contribution to journal › Article › peer-review

619   Link opens in a new tab Scopus citations

Fingerprint

Dive into the research topics of 'Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science

Keyphrases